| Identification | Back Directory | [Name]
3-[(2E)-4-[5-(Aminocarbonyl)-2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-7-[3-(4-morpholinyl)propoxy]-1H-benzimidazol-1-yl]-2-buten-1-yl]-2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-3H-imidazo[4,5-b]pyridine-6-carboxamide | [CAS]
2408723-12-4 | [Synonyms]
3-[(2E)-4-[5-(Aminocarbonyl)-2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-7-[3-(4-morpholinyl)propoxy]-1H-benzimidazol-1-yl]-2-buten-1-yl]-2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-3H-imidazo[4,5-b]pyridine-6-carboxamide | [Molecular Formula]
C40H48N14O6 | [MOL File]
2408723-12-4.mol | [Molecular Weight]
820.9 |
| Hazard Information | Back Directory | [Uses]
STING agonist-22 (CF501) is a potent non-nucleotide STING agonist. STING agonist-22 is a adjuvant by activating STING to induce the type I interferon (IFN-I) response and proinflammatory cytokine production. STING agonist-22 can be used as an adjuvant to boost the original protein vaccine, producing potent, broad, and long-term immune protection. STING agonist-22 can be used for SARS-CoV-2 variants and sarbecovirus diseases research[1]. | [in vivo]
STING agonist-22 (CF501) robustly, but transiently, activates innate immunity with acceptable safety profile in mice[1]. | Animal Model: | Balb/c mice (female, six weeks old)[1] | | Dosage: | 20, 75?μg | | Administration: | Intramuscular injection | | Result: | Although innate immunity was activated only transiently by CF501, it should be sufficient to stimulate the required humoral and cellular immune responses. The half-life of CF501 was 0.5?h and there was no detectable CF501 in the plasma after 2?h of the injection. |
| [References]
[1] Liu Z, et al. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Res. 2022 Mar;32(3):269-287. DOI:10.1038/s41422-022-00612-2 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|